I started a new academic position. Willing to teach and to perform research on frontier areas of medicinal chemistry. The research will be focused on structure-based drug design and hit identification, lead optimization, preclinical studies. Also, interested in ligand targeted drug conjugates for cancer and other diseases.

Worked as Marie Curie Individual Postdoctoral Fellow in the Drug Design Research group lead by Prof. Ana Ramos, and Prof. Beatriz de Pascual-Teresa Fernández, University of San Pablo CEU, Madrid, Spain.Project: An Integrated Computational and Experimental Approach to Rapid Synthesis of Highly Selective Dual-Targeted HDAC/CK2, MMP2/CK2 Inhibitors We designed a series of CK2/HDAC1 dual inhibitors provided with sub-nanomolar activity against both CK2 and HDAC1, therefore having… Show more Worked as Marie Curie Individual Postdoctoral Fellow in the Drug Design Research group lead by Prof. Ana Ramos, and Prof. Beatriz de Pascual-Teresa Fernández, University of San Pablo CEU, Madrid, Spain.Project: An Integrated Computational and Experimental Approach to Rapid Synthesis of Highly Selective Dual-Targeted HDAC/CK2, MMP2/CK2 Inhibitors We designed a series of CK2/HDAC1 dual inhibitors provided with sub-nanomolar activity against both CK2 and HDAC1, therefore having promising utility as dual-targeting agents for cancer. Remarkably, the best compound showed 3.0 and 3.5 times higher inhibitory activity than the reference single-targeted compounds CX-4945 (CK2 inhibitor in Phase 2 clinical trials) and SAHA (FDA approved HDAC inhibitor), respectively. This potent candidate exhibited micromolar activity in cell-based cytotoxic assays against multiple cancer cell lines. I spend my secondment period in Hospital La Fe (Valencia, Spain) under the supervision of Prof. Antonio Pineda to get experience in the main physicochemical techniques to study drug-target interactions, such as NMR techniques (STD and waterLOGSY), Isothermal Titration Calorimetry (ITC), and Surface Plasmon Resonance (SPR). I expressed Matrix metalloproteinase-13 (MMP13), a protein that plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA) and studied its interaction with MMP13 inhibitors designed in the group. Show less

Worked as a Postdoctoral Research Associate in Prof. Philip S Low Lab, Purdue Institute of Drug Discovery, Purdue University, United States (Jan 2016 to Dec 2017)‘Receptor Targeted delivery of MicroRNAs for cancer treatment’MicroRNAs are small RNAs that negatively regulate gene expression post-transcriptionally. Because changes in microRNA expression can promote or maintain disease states, microRNA-based therapeutics are being evaluated extensively. In this work, microRNAs are… Show more Worked as a Postdoctoral Research Associate in Prof. Philip S Low Lab, Purdue Institute of Drug Discovery, Purdue University, United States (Jan 2016 to Dec 2017)‘Receptor Targeted delivery of MicroRNAs for cancer treatment’MicroRNAs are small RNAs that negatively regulate gene expression post-transcriptionally. Because changes in microRNA expression can promote or maintain disease states, microRNA-based therapeutics are being evaluated extensively. In this work, microRNAs are delivered in the absence of a protective vehicle. The method relies on direct attachment of microRNAs to folate (FolamiR), which mediates delivery of the conjugated microRNA into cells that overexpress the folate receptor. We show that the tumor-suppressive FolamiR, FolamiR-34a, is quickly taken up both by triple-negative breast cancer cells in vitro and in vivo and by tumors in an autochthonous model of lung cancer and slows their progression. This method delivers microRNAs directly to tumors in vivo without the use of toxic vehicles, representing an advance in the development of non-toxic, cancer-targeted therapeutics.I have completed Purdue University hands-on training on ‘Animal handling’, Upon successful completion of all this training, I received my animal use qualification number (RAN-821) from Purdue Animal Care and Use Committee (PACUC). Show less

Worked as Swiss Government Excellence Postdoctoral Fellow at Prof. Gilles Gasser Lab, Inorganic Chemical Biology Laboratory, University of Zurich, Switzerland (2014 – 2015). Worked on 'Metallocene-Peptide Bioconjugates: Inhibition of CDC25B Phosphatase'CDC25 phosphatases are key cell cycle regulators and represent very attractive but challenging targets for anticancer drug discovery. Rudolph et al., from BASF recently published a pentapeptide (CDC1249), which specifically inhibits… Show more Worked as Swiss Government Excellence Postdoctoral Fellow at Prof. Gilles Gasser Lab, Inorganic Chemical Biology Laboratory, University of Zurich, Switzerland (2014 – 2015). Worked on 'Metallocene-Peptide Bioconjugates: Inhibition of CDC25B Phosphatase'CDC25 phosphatases are key cell cycle regulators and represent very attractive but challenging targets for anticancer drug discovery. Rudolph et al., from BASF recently published a pentapeptide (CDC1249), which specifically inhibits CDC25B enzyme and thus this peptide acted as potential drug for cancer. In this context, Loganathan et al has developed metallocene peptide bioconjugates (CDC1250) as CDC25B enzyme inhibitors. I am preparing a manuscript for submission. Parallelly, I worked on the development of organometallic anticancer Ru(II) arene complexes. In one year of research in this field, I generated substantial data resulting in two important publications. Show less

Under the supervision of Prof. M. Palaniandavar FRSC, FASc, FNA, Bharathidasan University, Tiruchirappalli, India (2009 – 2014)Thesis entitled ‘Studies on DNA and Protein Cleavage and Anticancer Activities of Mixed Ligand Copper(II) Complexes of Diimines’Fascinated by Metal-Nucleic acid research, I chose to work on ‘Mixed-Ligand Copper(II) and Ruthenium(II) Complexes of Diimines as Chemical Nuclease and Protease and their Anticancer Activities’ for my PhD. I have successfully isolated… Show more Under the supervision of Prof. M. Palaniandavar FRSC, FASc, FNA, Bharathidasan University, Tiruchirappalli, India (2009 – 2014)Thesis entitled ‘Studies on DNA and Protein Cleavage and Anticancer Activities of Mixed Ligand Copper(II) Complexes of Diimines’Fascinated by Metal-Nucleic acid research, I chose to work on ‘Mixed-Ligand Copper(II) and Ruthenium(II) Complexes of Diimines as Chemical Nuclease and Protease and their Anticancer Activities’ for my PhD. I have successfully isolated copper(II) and organometallic Ru(II)-arene complexes as cytotoxic drugs. The results of our systematic investigations are published in 10 articles and 1 book chapter.In-vitro Techniques Training: Hands-on training on “Techniques in Animal Cell Culture and In-vitro Toxicology”, Mahatma Gandhi-Doerenkamp Centre (MGDC) for Alternatives to Use of Animals in Life Science Education, Bharathidasan University, India, October 2 – 11 (10 days), 2013. Show less